Covered recipient · General Payments record
KORBIN ANDREW BRAY
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2023–2024
$300.54
- Reported across 17 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $280.73 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $131.89 | 7 |
| Lilly USA, LLC | $47.36 | 3 |
| Acerta Pharma LLC | $32.34 | 2 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $23.19 | 1 |
| DEXCOM, INC. | $17.05 | 1 |
| ABBVIE INC. | $15.05 | 1 |
| GlaxoSmithKline, LLC. | $13.85 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $15.05 | 07/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103364535 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.97 | 07/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105851456 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.37 | 11/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104595286 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $23.19 | 02/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117873363 | CMS |
| Dexcom, Inc. | $17.05 | 07/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153314778 | CMS |
| GlaxoSmithKline, LLC. | $13.85 | 11/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115899753 | CMS |
| Lilly USA, LLC | $18.82 | 01/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135139232 | CMS |
| Lilly USA, LLC | $14.63 | 05/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135109156 | CMS |
| Lilly USA, LLC | $13.91 | 11/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135115485 | CMS |
| Novo Nordisk Inc | $18.07 | 01/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096658721 | CMS |
| Novo Nordisk Inc | $22.90 | 03/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097421566 | CMS |
| Novo Nordisk Inc | $14.57 | 03/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097151136 | CMS |
| Novo Nordisk Inc | $18.11 | 04/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097011005 | CMS |
| Novo Nordisk Inc | $21.56 | 06/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096798580 | CMS |
| Novo Nordisk Inc | $15.15 | 07/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097291361 | CMS |
| Novo Nordisk Inc | $21.53 | 08/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096999030 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2023, 2024
- Source files
- Dataset page · Bulk file · PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.